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II. Abstract: 
Augmentation of mitochondrial oxidative metabolism by insulin might be mediated in part by 
induction of the inner mitochondrial membrane protein, Optic Atrophy-1 (OPA-1). Decreased OPA-
1 in skeletal muscle has been reported in both murine and human type II diabetic models. Reduced 
OPA-1 in these contexts correlates with mitochondrial content, oxidative capacity, and dynamics. In 
addition to increasing mitochondrial fusion, OPA-1 mediates cristae remodeling t o enhance 
mitochondrial bioenergetics through oligomer formation. Therefore, we hypothesized that insulin 
stimulation increases OPA-1 protein levels and mitochondrial respiration by increasing OPA-1 
oligomerization and cristae remodeling in skeletal muscle cells. To investigate the role of insulin on 
mitochondrial dynamics and cristae organization, Cre-LoxP technology was used to ablate OPA-1 from 
skeletal myoblasts isolated from floxed OPA-1 mice. Confocal microscopy and MitoTracker orange was 
employed to obtain three-dimensional images of mitochondria networks, and transmission electron 
microscopy (TEM) was used to analyze ultrastructure of mitochondrial cristae. Two hours of insulin 
treatment increased OPA-1 protein levels, promoted mitochondrial fusion, elevated mitochondrial 
respiration, increased cristae number along with volume density and area, decreased the distance of 
ER-mitochondria contacts, and it may have even changed OPA-1 oligomerization. Depletion of OPA-1 
and MFN-2 blocked the metabolic effects of insulin stimulation. OPA-1 depletion reduced cristae 
number, volume density, and area. Loss of OPA-1 resulted in a compensatory elevation of 
mitochondrial associated membrane proteins (MAMs), increasing the number of ER-mitochondria 
contacts, blocking OPA-1 oligomerization, and decreasing the ER-mitochondria contact distance. 
Together, ablation of OPA-1 alters metabolic responses to insulin in skeletal muscle cells. Furthermore, 
insulin stimulation promotes changes in cristae morphology and triggers mitochondrial fusion through 
an IR-pAKT pathway that increases OPA-1. ER-mitocontacts increase after ablation of OPA-1 due to 
an increase in MAMs. Lastly, Loss of OPA-1 inhibits OPA-1 oligomerization formation.  
 
III. Introduction: 
Background and Purpose: Diabetes and cardiovascular disease (CVD). Diabetes affects 29.1 million 
people in the United States, and another 86 million have prediabetes (26). Although 1 out of 11 people has 
diabetes, 1 out of 4 people are unaware (26). Diabetes disproportionately affects minorities, especially 
Native Americans and African Americans (26). Type 2 diabetes (T2DM) has been linked to alterations in 
mitochondrial oxidative metabolism in insulin responsive tissues, characterized by reduced mitochondrial 
content, and acquired or reduced submaximal ADP-stimulated oxidative phosphorylation and plasticity 
of mitochondria. T2DM is strongly related to insulin resistance (6), which is reduced responses in target 
tissues, such as skeletal muscle or  liver (6).  Insulin, produced by the pancreas, is a hormone that helps use 
energy from blood glucose. (6). Although β-cell failure is the condicio sine qua non of T2DM, skeletal 
muscle insulin resistance often is an early defect before hyperglycemia develops and β-cell failure occurs (6; 
15; 32). Notably, muscle lipid accumulation is associated with insulin resistance and T2DM in children and 
adults (9).  High blood glucose in adults with diabetes increases risk for stroke and manifestations of 
coronary 
artery disease such as angina, and heart attack (10; 12). People with T2DM have increased prevalence of high 
blood pressure, dyslipidemia, and obesity that independently contribute to high rates of CVD (1; 10; 12), 
which is the leading cause of death of people with diabetes (1; 4; 10). Although some interventions 
may increase oxidative phosphorylation, mitochondrial content and improve insulin resistance in some 
subjects (11), however, important gaps remain in our understanding of the link between mitochondrial 
dysfunction and insulin resistance. 
Mitochondrial Dynamics. Mitochondria are exceptional double membrane organelles (24). They act as 
cellular powerhouses producing large quantities of energy to maintain normal homeostasis. Mitochondria 
contain two membranes for specific functions—the outer membrane, which has pores to allow ions and 
small molecules to flow through and the inner membrane that houses the mitochondrial genome and the 
electron transport chain (18; 23; 24). These two mitochondrial membranes are dynamic and undergo 
constant cycling to maintain mitochondrial integrity, by mechanisms called fusion and fission (14; 18; 23; 
24). Mitochondrial fission and fusion play critical roles in protecting the mitochondria under diverse 
metabolic or environmental stresses (22). Fusion mitigates stress by amalgamating damaged mitochondria 
as a form of complementation whereas fission creates new mitochondria and functions to remove damaged 
mitochondria via mitophagy or to activate apoptosis (5; 35). Mitochondrial proteins that regulate outer 
membrane fusion belong to a GTPase family called Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2); whereas, 
Optic atrophy 1 (OPA1) controls the inner mitochondrial membrane fusion (7; 19; 30). Fusion of each 
membrane is distinct (14; 18; 20; 23; 24). Interestingly, the inner membrane regulates mitochondrial cristae 
morphology in part by generation of OPA1 oligomers (7; 19; 22). These oligomers of OPA1 are assembled 
at the base of the mitochondrial cristae to narrow the width (7; 19; 22). Conversely, mitochondrial fission is 
mediated by interactions between two proteins, Mitochondrial fission 1 protein (Fis1), found in the 
outer membrane and a cytosolic protein, Dynamin-1-like protein (Drp1) (14; 18; 22; 23; 30). For fission to 
occur, Drp1 translocates to the mitochondria. Post-translational modifications also regulate Drp1, and these 
include phosphorylation, ubiquitination, or sumoylation (27; 31; 33). Although mitochondrial dynamics 
uses different proteins, germline, conditional, and specific tissue mutations show that altered mitochondrial 
fusion or fission proteins are deleterious for mitochondrial homeostasis suggesting these proteins are 
essential for maintaining healthy mitochondria. 
OPA1 and Insulin Signaling. Mitochondria are central to insulin action in skeletal muscle. Importantly, 
skeletal muscle mitochondrial dysfunction may lead to fat accumulation in the skeletal muscle, which is 
implicated in the initial stages of the development of insulin resistance. We reported that insulin increased 
mitochondrial fusion and oxidative capacity in vivo and in-vitro in skeletal muscle. Increased 
mitochondrial connectivity is associated with increased crista density. Mechanistically, insulin increases 
OPA1 mRNA and protein via AKT-mTOR-NFKB transcriptional regulation of the OPA1 promoter (21). 
Notably, silencing OPA1 or Mfn1 in vitro prevented insulin- mediated stimulation of mitochondrial 
metabolism. OPA1 oligomerization improves efficiency of the electron transport chain and activity of 
ATP synthase (21). Oligomerization of OPA1 is independent of its capability to promote mitochondrial 
fusion (21). Mutations in OPA1, which lack the GTPase domain, maintain oligomerization, which is 
sufficient to increase efficiency of hepatic mitochondria after short-term nutrient deprivation (22). However, 
it is unknown if insulin signaling increases OPA1 oligomerization, and whether this mechanism contributes 
to OPA1-dependent activation of mitochondrial function following insulin stimulation. 
 
IV. Materials and methods: 
C2C12 and Human Cell Culture: 
Mouse skeletal muscle C2C12 cells were maintained in HG DMEM containing 4.5 g/l glucose (Lonza, Basel, 
Switzerland) enhanced with 10% heat inactivated Fetal Bovine Serum (FBS) (Gibco/Life Technologies, 
Carlsbad, CA, USA), 100 μg/ml penicillin and 100 μg/ml streptomycin (Lonza) (growth medium) to maintain 
myoblasts Differentiation was started when cells reached ~70–80% confluence (day 0).Differentiation was 
induced by switching from growth medium to HG DMEM containing 4.5 g/l glucose supplemented with 2% 
Horse Serum (Gibco/Life Technologies), 100 μg/ml penicillin and 100 μg/ml streptomycin (differentiation 
medium) to form myotubes.  
Primary Cell culture: 
Satellite cell isolation was performed as previously described [11].  
Western blotting: 
To obtain total protein extracts from differentiated myotubes, cells were washed with ice-cold PBS before 
adding cold lysis buffer (25 mM Tris HCL pH = 7.9), 5 mM MgCl2, 10% glycerol, 100 mM KCl; 1% NP40; 
0.3 mM dithiothreitol, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 
containing freshly added protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany).  Cells 
were scraped, homogenized with a 25-gauge needle, and centrifuged at 14,000 rpm for 10 min at 4 °C. 
Supernatants were collected and boiled with Laemmli sample buffer. Cell lysates were subjected to SDS-
Page and proteins were transferred to nitrocellulose membranes (BioRad, Berkeley, California, USA). 
Membranes were blocked with 3% BSA-TBST and incubated with anti-AMPKα, anti-phospho-AMPKα, 
anti-GRP 75, anti-PACS2, anti-OPA1, anti-fis1, anti-MFN1, anti-MFN2, anti-Drp1, anti-Drp1-673, anti-
Drp1-616, and anti-Actin. Quantification was carried out using ImageJ 1.49 m. For statistical analysis 
Student T-tests were used. 
 
Antibodies: 
Primary Antibodies: OPA1 (1:1,000, BD Biosciences, San Jose, CA, USA, #612606), FGF21 (1: 1,000, 
Abcam, Cambridge, UK #ab171941), GAPDH (1: 1,000, Cell Signaling Technology, Danvers, MA, USA, 
#2118), AMPK (1: 1,000, Cell Signaling Technology #2793), phospho-AMPK (1: 1,000, Cell Signaling 
Technology #4181), Mfn1 (1: 1,000, Abcam #ab57602), Mfn2 (1: 1,000, Abcam # ab101055), GRP 75, 
Drp1, Drp 673, Drp 616. Secondary antibodies: IRDye 800CW anti-mouse (1:10,000, LI-COR, Lincoln, NE, 
USA, #925- 32212) and Alexa Fluor anti-rabbit 680 (1: 10,000, Invitrogen #A27042). Fluorescence was 
quantified using the LiCor Odyssey imager. 
 
 V. Results: 
Figure 1: Cell Line Development 
 
 
Figure 2: Insulin Stimulation Increases OPA-1 in C2C12 Myoblasts 
 
Figure 2A. Representative Western blot image of OPA-1 expression in C2C12 myoblasts after insulin treatment. Figure 2B. 
Quantification of OPA-1 expression in C2C12 myoblasts after insulin treatment. Figure 2C. Representative Western blot image of 
pAKT/tAKT ratio in C2C12 myoblasts after insulin treatment. Figure 2D. Quantification of pAKT/tAKT ratio in C2C12 myoblasts after  
insulin treatment.  
 
 
 
 
 
Figure 3: Insulin Stimulation Increases OPA1 in C2C12 Myotubes 
 
Figure 3A. Representative Western blot image of OPA-1 expression in C2C12 myotubes after insulin treatment. Figure 3B. 
Quantification of OPA-1 expression in C2C12 myotubes after insulin treatment. Figure 3C. Representative Western blot image of 
pAKT/tAKT ratio in C2C12 myotubes after insulin treatment. Figure 3D. Quantification of pAKT/tAKT ratio in C2C12 myotubes after 
insulin treatment. 
 
Insulin increases the levels of Mitochondrial OPA-1 protein in C2C12 myoblasts and C2C12 myotubes: We 
previously published that insulin increases OPA1 levels and mitochondrial function in neonatal ventricular myocytes 
and L6 myoblasts [1], in parallel with increased mitochondrial fusion. C2C12 myoblasts were plated in 10% FBS 
DMEM, and switched 48 hours later to a low-serum medium (2% FBS DMEM) for 12 hours. Myotubes were 
differentiated in 2% horse serum. Cells were then treated with insulin (10nM/L) for up to 6 hours and analyzed at two-
hour intervals. Cells were collected for Western blot analysis. Western blot for OPA-1 demonstrated that insulin 
treatment increases OPA-1 protein levels over the 6-hour time course in C2C12 myoblasts (Figure 2A and Figure 2B) 
and C2C12 myotubes (Figure 3A and Figure 3C). Insulin treatment also increased phosphorylation of AKT at Ser 473 
in C2C12 myoblasts (Figure 2C and Figure 2D) and C2C12 myotubes (Figure 3C and Figure 3D). 
 
 
 
 
 
 
Figure 4: Insulin Stimulation Increases OPA1 in Primary Myoblasts
Figure 4A. 
Representative Western blot image of OPA-1 expression after insulin treatment in myoblasts. Figure 4B. Representative Western 
blot image of pAKT/tAKT ratio after insulin treatment in myoblasts. Figure 4C. Quantification of OPA-1 expression after insulin 
treatment in myoblasts. Figure 4D. Quantification of pAKT/tAKT ratio after insulin stimulation in myoblasts. Figure 4E. Western blot 
image and Quantification  of Fusion and Fission proteins after insulin stimulation in myoblasts. Figure 4F. Western blot image and 
Quantification of  OXPHOS proteins after insulin stimulation in myoblasts. Figure 4G-4I. Seahorse OCR with and without insulin 
stimulation for 2 hours, (G) 4 hours (H), and 6 hours (I) in myoblasts. 
 
Figure 5: Insulin Stimulation Increases OPA1 in C2C12 Myotubes
 
Figure 5A. Representative Western blot image of OPA-1 expression after insulin treatment in myotubes. Figure 5B. Representative 
Western blot image of pAKT/tAKT ratio after insulin treatment in myotubes. Figure 5C. Quantification of OPA-1 expression after 
insulin treatment in myotubes. Figure 5D. Quantification of pAKT/tAKT ratio after insulin stimulation in myotubes. Figure 5E. 
Western blot image and Quantification  of Fusion and Fission proteins after insulin stimulation in myotubes. Figure 5F. Western blot 
image and Quantification of OXPHOS proteins after insulin stimulation in myotubes. Figure 5G-5I. Seahorse OCR with and without 
insulin stimulation for 2 hours, (G) 4 hours (H), and 6 hours (I) in myotubes. Figure 5J. Westernblot image and Quantification of 
Mitochondrial Biogenesis Markers in myotubes.  
 
Insulin Increases Levels of Mitochondrial OPA-1 Protein in Primary Myoblasts and Primary Myotubes without 
Changing Mitochondrial Biogenesis and Increases Mitochondrial Oxygen Consumption: To investigate the role 
of insulin stimulation on OPA-1, we utilized a primary in vitro system. Isolation of primary satellite cells were from 
OPA-1 male floxed mice (Figure 1). Subsequently, cells were plated in 10% FBS DMEM, and switched 48 hours later 
to a low-serum medium (2% FBS DMEM) for 12 hours. Myotubes were differentiated in 2% FBS serum and insulin 
transferrin selenium. Primary myoblasts were then validated using either immunocytochemistry markers of skeletal 
muscle (Figure 1A and Figure 1B) and primary myotubes were validated by bright field morphology (Figure 1C or 
Figure 1D). Cells were then treated with insulin (10nmol/L) for up to 6 hours and analyzed at two-hour intervals to 
elucidate the mechanism of insulin dependent mitochondrial fusion by OPA-1. Western blot analysis showed that 
insulin stimulation increased total content of OPA-1 protein levels at 2 and 4 hours (Figure 4A and Figure 4C) in 
primary myoblasts and primary myotubes (Figure 5A and Figure 5C). As a positive control, cell lysate was used to 
determine if the insulin stimulation worked in primary myoblast (Figure 4B and Figure 4D) and primary myoblasts 
(Figure 5B and Figure 5D) by measuring the activation of AKT at site Ser 473. Insulin stimulation increased AKT at site 
Ser 473 at 2 hours and 4 hours of insulin stimulation. 
 
Notably, insulin stimulation did not change MFN-1, DRP-1, FIS-1, and MFN-2 protein expression in primary myoblasts 
(Figure 4E) and primary myotubes (Figure 5E). To determine whether the changes observed in OPA-1 occurred in 
conjunction with an increase in mitochondrial biogenesis, we evaluated changes in total mitochondrial mass by 
quantifying three core proteins of the OXPHOS machinery. Insulin did not change the level of any of these 
components (Figure 4F and Figure 5F). An increase in OPA-1 protein level has been associated with improved 
mitochondrial capacity and associated with mitochondrial fusion. To assess mitochondrial capacity, we used 
searhorseXF-24 to quantify the changes of insulin stimulation on mitochondrial OXPHOS. Insulin promoted a rise in 
both baseline and FCCP- uncoupled maximum cellular oxygen consumption after 2 hours and 4 hours of insulin 
treatment in primary myoblasts (Figure 4G and Figure 4H) and at 2 hours in primary myotubes (Figure 5G and Figure 
5H). However, prolonged stimulation of insulin (6 hours) resulted in no oxygen consumption changes (Figure 4I and 
Figure 5I). Although, OXPHOS machinery did not change, we further investigated if mitochondrial biogenesis was 
increased to account for the changes in OPA-1 protein expression. Western blot analysis demonstrated that PGC1α, 
a master regulator of mitochondrial biogenesis did not change in myotubes (Figure 5J). 
 
Figure 6: OPA1 Deletion Decreases Mitochondrial Capacity in Primary Myoblasts and 
Myotubes 
Figure 6A. 
Representative Western blot image of OPA-1 deletion in Primary OPA-1 floxed myoblasts Figure 6B. Quantification of Western blot 
image of OPA-1 deletion in Primary OPA-1 floxed myoblasts. Figure 6C. Seahorse measurement of mitochondrial respiration (OCR) 
after Primary deletion of OPA-1 in myoblasts. Figure 6D. Representative Western blot image of OPA-1 deletion in Primary OPA-1 
floxed myotubes. Figure 6E. Quantification of Western blot image of OPA-1 deletion in Primary OPA-1 floxed myotubes.  Figure 6F. 
Seahorse measurement of mitochondrial respiration (OCR) after Primary deletion of OPA-1 in myotubes. 
 
Figure 7: Downregulation of OPA1 alters the metabolic response to insulin in primary 
myotubes 
Figure 7A. 
Representative Western blot image of OPA-1 deletion in Primary OPA-1 floxed myotubes that have been stimulated with and 
without insulin. Figure 7B. Quantification of Western blot image of OPA-1 deletion in Primary OPA-1 floxed myotubes that have 
been stimulated with and without insulin. Figure 7C. Seahorse measurement of mitochondrial respiration (OCR) after Primary 
deletion of OPA-1 in myotubes and stimulation with insulin.  
 
 
Downregulation of OPA-1 Alters the Metabolic Responses to Insulin in Primary Myotubes: To determine if 
mitochondrial fusion changes are directly related to the effects of insulin on mitochondrial function, we made primary 
satellite cells from male OPA-1 floxed mice and cells were grown to produce myoblasts in (20% FBS) or differentiated 
into primary myotubes (2%). After the two primary cell lines were established, cells were infected with a GFP-
expressing adenovirus (AD-GFP) or with an adenovirus expressing a GFP-tagged CRE recombinase. Ablation of OPA-
1 in primary myoblast was confirmed by Western blot (Figure 6A and Figure 6B). After 48 hours deletion, oxygen 
consumption was measured by SeahorseXF-24 and we determined that loss of OPA-1 lowered the ability for the cells 
to respire (Figure 6C). Western blot analysis determined that OPA-1 was ablated in primary myotubes (Figure 6D and 
Figure 6E) and showed similar oxygen consumption results as primary myotubes (Figure 6F). Short-term deletion of 
OPA-1 blocked 2-hour insulin mediated increase in oxygen consumption (Figure 7C). Together, without OPA-1 the 
metabolic responses of insulin are altered in primary myotubes. 
 
Figure 8: Insulin Stimulation Promotes Fusion in the Absence of OPA1 
 
 
 
Figure 8A. Representative TEM image of primary myoblasts that received deletion of  OPA-1 with or without insulin. Figure 8B-
Figure 8D. Circulatory Index (8B), Mitochondrial Area (8C), and Mitochondrial Number (8D) of  primary myoblasts that received with 
or without insulin.  
 
 
 
 
 
 
 
 
 
 
Figure 10: Ablation of IR/IGF-R blocks insulin mediated fusion in Myoblasts 
 
Figure 10. 10A. Westernblot of IR and IGF-R after deletion in primary myoblasts. 10B. Western blot Densitometry of IR from Figure 
10A after deletion in primary myoblasts. 10C. Western blot Densitometry of IGF-R after deletion from Figure 10A in primary 
myoblasts.  10D. Representative TEM image of primary myoblasts that received deletion of IGF-R/ IR with or without insulin. Figure 
10B-Figure 10D. Circulatory Index (10B), Mitochondrial Area (10C), and Mitochondrial Number (10D) that received deletion of  IGF-
R/ IR  with or without insulin. 
 Insulin Increases Mitochondrial Fusion in Cultured Primary Myoblasts through an IR-pAKT pathway: To 
examine detailed changes in mitochondrial morphology in response to insulin stimulation, we performed electron 
microscopy analysis in primary myoblasts. The data demonstrated that insulin stimulation for 2 hours decreased 
circulatory index (Figure 8A and Figure 8B, increased mitochondrial area (Figure 8A and Figure 8C), and decreased 
mitochondrial number (Figure 8A and Figure 8D). To determine whether the mitochondrial morphology changes are 
directly related to the effects of insulin on mitochondrial function, we ablated OPA-1 using adenovirus. Interestingly, 
knockdown of OPA-1 increased circulatory index compared to its control (Figure 8A and Figure B), increased 
mitochondrial area (Figure 8A and Figure 8C), and did not increase mitochondrial number (Figure 8A and Figure D). 
Notably, OPA-1 ablation in conjunction with insulin stimulation for 2 hours did not prevent mitochondrial morphology 
changes. We observed that after 2 hours of insulin stimulation, circulatory index decreased (Figure 8A and Figure 8B), 
mitochondrial area increased (Figure 8A and Figure 8C), and the number of mitochondria decreased in primary 
myoblasts (Figure 8A and Figure 8D). This would suggest that insulin might be able to regulate inner membrane fusion 
independently of OPA-1 ability to mediate mitochondrial metabolism changes. More importantly, to confirm that insulin 
signaling is required to promote fusion of mitochondria, we ablated IR and IGF-R from primary myoblasts and 
demonstrated that we were able to successfully ablate IR and IGF-R ( Figure 9A – Figure 9C). Next , we  performed 
electron microscopy analysis in ablated IR and IGF-R primary myoblasts that either received insulin stimulation for 
2hours or did not receive insulin stimulation (Figure 9D). The data demonstrated that insulin stimulation for 2 hours 
decreased circulatory index (Figure 9D and Figure 9E, increased mitochondrial area (Figure 9D and Figure 9F), and 
decreased mitochondrial number (Figure 9D and Figure 9G). To determine whether the mitochondrial morphology 
changes are directly related to the effects of insulin on mitochondrial function, we ablated  IR and IGF-R  using 
adenovirus and stimulated cells with or without insulin.  Notably, after ablation of IR and IGF-R in primary myoblasts, 
insulin was not able to alter mitochondrial morphology under the following paramters: circulatory index (9E), 
mitochondrial area (9F), mitochondrial number (9G),  (Figure 9E to Figure 9G). 
 
 
Ablation of OPA-1 Increases ER-Mito Contacts in Myoblasts: It has been shown that OPA-1 deficiency promotes 
secretion of FGF-21 from muscle that prevents obesity and insulin resistance in a mutant model [2]. Similarly, in 
skeletal muscle cells, ablation of OPA-1 results in ER stress and FGF-21 protein level increase [2]. Ablation of OPA-1 
leads to an increase in the levels of MFN-1 and MFN-2 [2], which are components of the mitochondrial-associated 
membrane proteins (MAMs). MAMS are proteinaceous tethers that connect the endoplasmic reticulum with 
mitochondria [3]. Notably, MAMs use a specialized subcompartment at the connects of ER and mitochondria to 
maintain efficient transfer of calcium from the ER to Mitochondria, help drive proper mitochondrial bioenergetics, and 
lipid synthesis [3]. MAMS are believed to regulate mitochondrial shape and motility, and assist with the formation of 
autophagosome assembly. Most importantly, MAMs have been shown to be a place of significant activity for the 
transfer of stress signals from the ER to the mitochondria. Interestingly, in our OPA-1 deficient primary myoblasts 
(Figure 9A and Figure 9B) and OPA-1 deficient primary myotubes (Figure 10 A and Figure 10B), we observed an 
increase in FGF-21 protein levels (Figure 9C and Figure 9D) and (Figure 10 C and Figure 10 D) and BIP (GRP78), a 
molecular chaperone (Figure 9 E and Figure 9 F) and (Figure 10 E and Figure 10F). Additionally, ablation of OPA-1 
increased expression of MFN-1 and MFN-2 in primary myoblasts (Figure 9G- 9I) and primary myotubes (Figure 10 G-
Figure 10 I), a tethering protein. Additionally, we found that loss of OPA-1 increased MCU protein levels and SERCA 
protein levels in myoblasts (Figure 9J-Figure 9L) in primary myotubes (Figure 10J- Figure 10L). To determine if the loss 
of OPA-1 increased MAMs, we used electron microscopy. We found that loss of OPA-1 increases the formation of ER-
Mitocontacts in primary myoblasts in size of the contact with mitochondria (Figure 11A and Figure 11B), but did not 
change the size of the interaction with the endoplasmic reticulum (Figure 11A and Figure 11C). Interestingly, the size of 
each MAM was increased with the deletion of OPA-1 (Figure 11D). 
 
 
 VI. Discussion 
Data is going toward publication so we would like refrain from discussing findings.  
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